Company Overview
| Stock Name | 興科蓉醫藥控股有限公司 |
|---|---|
| Stock Code | 06833 |
| Company Full Name | 興科蓉醫藥控股有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要於中國從事血漿藥品、抗生素及其他藥品的市場營銷、推廣及渠道管理服務。 |
| Listing Date | 2016-03-10 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國四川省成都市高新區天府大道北段1700號環球中心E5-1805室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.sinco-pharm.com |
| Share Registrar | |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 0.80 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 6.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 32,000,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 0.8 |
|---|---|
| First Day Open | HK$ 0.9 |
| First Day Change | -73.50% |
| First Day Volume | 149292000.0 |
| First Day Turnover | 131237000.0 |
Use of Proceeds
| Use of Proceeds | 1、約45%（約146.2百萬港元）將用于(i)收購新產品的銷售及經銷權；及(ii)收購醫藥行業具備專有知識產權或增長潛力的企業； 2、約33%（約107.2百萬港元）將不可撤回地用作償還本集團尚未償還的部分貸款及銀行貿易信貸； 3、約14%（約45.5百萬港元）將用于在四川雙流保稅區開發冷鏈設施及研發基地,預期冷鏈設施竣工后會成為中國西南地區最大的冷鏈設施之一； 4、約8%（約26.0百萬港元）將用作營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
招商证券（香港）有限公司 CE AAI650
Overall Coordinators (1)
招商证券（香港）有限公司 CE AAI650
Joint Bookrunners (1)
招商证券（香港）有限公司 CE AAI650
Joint Lead Managers (1)
招商证券（香港）有限公司 CE AAI650
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Prestigious Leader Limited | 50,000,000 HKD | — | 3.90% | — | 6 months | 2016-09-10 |
| 2 | 四川惠丰投资发展有限责任公司 | 38,758,400 HKD | — | 3.00% | — | 6 months | 2016-09-10 |
Directors & Management
| Chairman | To be extracted |
|---|---|
| Company Secretary | 彭云璐 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 黃祥彬(51.65%) |
|---|
